| Title |
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, September 2014
|
| DOI | 10.1007/s00280-014-2576-8 |
| Pubmed ID | |
| Authors |
J. Mateo, J. Berlin, J. S. de Bono, R. B. Cohen, V. Keedy, G. Mugundu, Lianglin Zhang, A. Abbattista, C. Davis, C. Gallo Stampino, H. Borghaei |
| Abstract |
A first-in-human clinical trial of a fully human, Fc-engineered IgG1 monoclonal antibody targeting integrin α5β1 was conducted to evaluate tolerability, maximum tolerated dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity. |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 44 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 20% |
| Student > Ph. D. Student | 8 | 18% |
| Student > Master | 5 | 11% |
| Student > Bachelor | 4 | 9% |
| Other | 4 | 9% |
| Other | 9 | 20% |
| Unknown | 6 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 24% |
| Agricultural and Biological Sciences | 7 | 16% |
| Biochemistry, Genetics and Molecular Biology | 6 | 13% |
| Nursing and Health Professions | 3 | 7% |
| Psychology | 3 | 7% |
| Other | 8 | 18% |
| Unknown | 7 | 16% |